Braze shares are surging today following the announcement that Salesforce has entered into a definitive agreement to acquire the customer engagement platform for approximately $5.66 billion in an all-cash transaction. Under the terms of the deal, Braze stockholders will receive $47.50 per share, representing a substantial premium over the stock's previous closing price. The acquisition is intended to integrate Braze's real-time AI marketing and messaging capabilities into Salesforce's Marketing Cloud and Data 360 platforms.

Braze  ·  Updated Oct 20

Lionsgate Studios (LION) shares are surging today following reports that Legendary Entertainment has revived talks regarding a potential acquisition of the company. This significant upward movement is driven by renewed takeover interest, which follows months of speculation and pressure from activist investors for the studio to explore a strategic sale.

Lionsgate Studios  ·  Updated Oct 20

Sellas Life Sciences Group (SLS) is surging today following the release of encouraging preclinical data demonstrating that its candidate SLS009 is active in pancreatic cancer organoid models, including those resistant to current RAS inhibitors. The upward movement is further supported by intense retail speculation regarding a potential buyout or major corporate update after the CEO’s 15th-anniversary message stated the company is entering its next chapter. Additionally, investor sentiment is high as the company approaches the final analysis trigger for its pivotal Phase 3 REGAL trial in acute myeloid leukemia.

SELLAS Life Sciences Group  ·  Updated Oct 20

Klaviyo shares are surging today following news that Salesforce has agreed to acquire its rival, Braze, for approximately $5.66 billion, a deal that validates the sector's valuation and positions Klaviyo as a primary standalone public asset and potential acquisition target. The stock is also gaining momentum from the announcement of a multiyear partnership with the Atlassian Williams F1 Team, which signals the company's ability to secure high-profile enterprise clients. These company-specific catalysts have effectively countered recent analyst downgrades, driving the stock up by more than 11 percent on unusually high trading volume.

Klaviyo, Inc. Class A  ·  Updated Oct 20

EquipmentShare.com is declining today as persistent skepticism surrounding short-seller allegations of undisclosed liabilities and accounting irregularities continues to overshadow the company's recent upward revision of its 2026 financial guidance. The stock's downward momentum is being fueled by a series of analyst price target cuts, including a reduction to 17 dollars by Citigroup, and a broader sell-off in high-leverage small-cap stocks. This movement reflects a sell-the-news reaction where improved outlooks are being discounted against ongoing concerns regarding the company's capital-intensive business model and transparency.

EquipmentShare.com, Inc.  ·  Updated Oct 20

Shares of Telkom Indonesia are rising significantly today due to strong value hunting and a technical rebound after the stock reached deeply oversold territory and a 52-week low in the previous session. Investor sentiment is also being bolstered by positive outlooks following an infrastructure unit spinoff and anticipation of the company's upcoming third-quarter earnings report. This movement appears to be a company-specific recovery from recent selling pressure rather than a broader sector trend.

PT Telekomunikasi Indonesia Tbk  ·  Updated Oct 20

Equifax is rising significantly today after reporting third-quarter 2026 adjusted earnings of $2.26 per share, which exceeded the analyst consensus of $2.20. The stock's gains are fueled by a 10% year-over-year revenue increase to $1.69 billion, reflecting strong performance in its Diversified Markets segment and a 15% rise in mortgage-related revenue despite a difficult broader market. This company-specific surge suggests investors are focusing on the earnings beat and operational resilience rather than the company's cautious guidance for the upcoming fourth quarter.

Equifax  ·  Updated Oct 20

Hasbro shares are climbing today after the company reported third-quarter 2026 earnings and revenue that significantly beat Wall Street estimates, fueled by record performance from its Magic: The Gathering franchise which surpassed 600 million dollars in quarterly revenue for the first time. The stock's upward movement is further supported by management raising its full-year financial guidance and doubling its 2026 share-repurchase target to 400 million dollars, reflecting strong operational momentum and investor confidence.

Hasbro  ·  Updated Oct 20

Sphere Entertainment is trading significantly higher today as the stock stages a technical recovery from recent oversold conditions, bolstered by news of a substantial institutional share purchase by Assenagon Asset Management reported over the weekend. The upward momentum is further supported by the ongoing commercial success of the sold-out Metallica residency at the Las Vegas venue and a recent Buy rating reaffirmation from Goldman Sachs. This company-specific move indicates a positive shift in investor sentiment following a period of volatility and recent analyst downgrades earlier in the month.

Sphere Entertainment  ·  Updated Oct 20

Heartflow, Inc. is trading significantly higher today following reports of favorable clinical adoption for its AI-driven cardiac imaging platform and a price target increase from Piper Sandler, which cited the company's strong competitive moat. The stock's gains are further supported by a broader sector-wide rally in healthcare technology and the shares reaching a new 52-week high. This upward movement reflects sustained investor optimism regarding the company's scaling platform and its software-like gross margins.

HeartFlow, Inc.  ·  Updated Oct 21

Hesai Group shares are rising significantly today following the company's announcement that it will report its third-quarter 2026 financial results on November 10, alongside its strategic rebranding as a physical AI infrastructure company. This upward momentum is further supported by positive market sentiment surrounding the recent launch of the Kosmo 3D World Data Engine and analyst reports suggesting the stock is substantially undervalued relative to its intrinsic fair value. The move is primarily company-specific, reflecting investor optimism about Hesai's leading position in the global LiDAR market and its expanding applications in autonomous mobility.

Hesai Group Sponsored ADR  ·  Updated Oct 20

Clover Health is moving significantly higher today as investors react to the company's recent achievement of a 5-Star CMS rating for its 2027 Medicare Advantage PPO plans and top rankings in U.S. News and World Report's 2027 Medicare Advantage ratings. This company-specific catalyst is driving strong market sentiment as the high ratings are expected to secure significant federal quality bonus benchmarks and enhance the company's competitive position in member recruitment. The upward movement reflects continued Medicare momentum following these regulatory and industry accolades, which validate the company's operational performance and future revenue potential.

Clover Health Investments  ·  Updated Oct 20

monday.com shares are rising significantly due to continued investor enthusiasm following the October 19 launch of its Harmony voice AI platform and its recent recognition as a leader in the 2026 Gartner Magic Quadrant. This upward momentum is further supported by a broader market rotation into high-growth software stocks as AI-driven growth narratives regain favor, coupled with the company's recent upgrade to a Zacks Rank 1 Strong Buy designation.

Monday.com  ·  Updated Oct 21

Relay Therapeutics is a top gainer today as the stock continues to rally following positive Phase 2 clinical data for its lead candidate, zovegalisib, which demonstrated a 60% volumetric response rate in treating vascular anomalies. The upward movement is further amplified by a series of recent analyst price target increases and high short interest, which appears to be fueling a short squeeze. This company-specific momentum reflects growing investor confidence in the company's precision medicine pipeline and its ongoing Phase 3 ReDiscover-2 study.

Relay Therapeutics  ·  Updated Oct 21

Revolution Medicines (RVMD) is trading significantly higher today following the announcement of key late-stage development milestones, including the initiation of patient treatment in new global Phase 3 clinical trials for its RAS(ON) G12D-selective inhibitor, zoldonrasib. The stock is also benefiting from bullish analyst commentary and price target increases as investors react to the commercial momentum of its recently FDA-approved oncology drug, RASONQUE. This company-specific rally reflects strong market confidence in the execution and depth of the firm's precision oncology pipeline.

Revolution Medicines  ·  Updated Oct 20

Spyre Therapeutics is trading significantly higher today following the presentation of clinical and preclinical data for its SPY001, SPY002, and SPY003 programs at the United European Gastroenterology Week 2026 conference. The stock's upward movement is further driven by Jefferies naming the company a top pick in the biotechnology sector, citing the potential for its long-acting antibody combinations to provide best-in-class efficacy for inflammatory bowel disease. This rally also reflects a rebound as investors capitalize on an attractive entry point following the company's recently closed public offering.

Spyre Therapeutics  ·  Updated Oct 20

Viridian Therapeutics (VRDN) is moving significantly higher today following the announcement of positive topline results from its Phase 3 THRIVE clinical trial evaluating veligrotug (VRDN-001) in patients with active thyroid eye disease (TED). The trial met its primary endpoint with a 70% proptosis responder rate compared to just 5% for the placebo group, while also achieving all secondary endpoints with high statistical significance and a favorable safety profile. This company-specific catalyst has driven substantial investor optimism as the company prepares for a potential Biologics License Application (BLA) submission in the second half of 2025.

Viridian Therapeutics  ·  Updated Oct 20

XPeng shares are rising significantly today as investors focus on the long-term value of its technology licensing partnership with Volkswagen, despite reports of slow initial sales for their first collaborative vehicle. The stock is also benefiting from strong third-quarter delivery data and positive momentum following the global debut of the G9L flagship SUV at the Paris Motor Show, which underscores the company's successful expansion into the European market. This company-specific movement is further amplified by a technical rebound as shares recover from recent multi-year lows.

XPeng, Inc. ADR  ·  Updated Oct 20

Casella Waste Systems shares are climbing today after activist investment firm Jana Partners disclosed a new position in the company and called for significant operational improvements to boost profit margins and returns on capital. During an investor summit, Jana Partners urged the waste management firm to target a 27 percent EBITDA margin by 2029 and better align executive compensation with shareholder value. This significant upward movement is company-specific, driven by market anticipation of potential strategic shifts and enhanced operational execution under activist pressure.

Casella Waste  ·  Updated Oct 20

BILL Holdings (BILL) is moving significantly higher today following the announcement of a first-of-its-kind live pilot program in partnership with Visa and Billtrust to enable trusted AI agents to automate end-to-end invoice payments. This collaboration utilizes Visa’s Trusted Agent Protocol to allow AI agents to securely authenticate and complete transactions through supplier portals, addressing a major historical barrier to payment automation. Investor sentiment is further bolstered by the company’s announcement that it has surpassed $2 trillion in cumulative total payment volume and launched new AI-native capabilities specifically designed for finance teams.

Bill.com Holdings  ·  Updated Oct 20

Erasca (ERAS) shares are rising significantly today in sympathy with its primary competitor, Revolution Medicines (RVMD), which announced the commencement of a Phase 3 trial for its RAS-targeting candidate and received a notable analyst upgrade. This sector-wide momentum is further bolstered by recent institutional support, including a major position increase by Assenagon Asset Management, and a strategic leadership realignment aimed at streamlining the development of Erasca's lead pan-RAS programs. The move reflects growing investor confidence in the precision oncology space ahead of the company's scheduled clinical data presentations in November.

Erasca  ·  Updated Oct 20

Tango Therapeutics is rising significantly today following the release of clinical trial abstracts for the 2026 ESMO Congress, which provided updated Phase 1/2 data for its lead candidate, vopimetostat, in combination with RAS inhibitors for pancreatic and lung cancer. The stock's momentum is further supported by recent bullish analyst initiations and a Positive Catalyst Watch designation from JPMorgan ahead of the full data presentation scheduled for later this week. This move is company-specific and reflects high investor expectations for the clinical progress of the company's precision oncology programs.

Tango Therapeutics  ·  Updated Oct 20

Arcus Biosciences is rising significantly today following the presentation of clinical data for casdatifan, its investigational kidney cancer treatment, during a highly anticipated investor event. Although the stock initially faced volatility, it surged as analysts highlighted the drug's competitive performance in clear cell renal cell carcinoma and its potential as a significant commercial opportunity. This company-specific movement is driven by positive market reception of the ARC-20 study results and follows recent bullish initiations from several major research firms.

Arcus Biosciences  ·  Updated Oct 20

Guidewire Software is moving significantly higher today following a positive research report from Information Services Group that highlighted the company's cloud migration ecosystem as a primary driver for insurance industry modernization. The stock is also gaining momentum ahead of its annual Connections conference and Analyst Day scheduled for next week, where investors anticipate updates on AI-driven platform innovations. This upward move is occurring despite recent disclosures of minor insider and institutional share sales, which have been overshadowed by strong analyst sentiment and price target increases.

Guidewire  ·  Updated Oct 20

Vicor Corporation shares are rising significantly today following a blowout third-quarter 2026 earnings report that exceeded analyst expectations for both revenue and earnings per share. The company reported a 78.5 percent year-over-year revenue increase and a record backlog of 406 million dollars, fueled by high demand for its Vertical Power Delivery technology in the AI infrastructure market. This company-specific movement reflects investor optimism regarding Vicor's transition to a high-margin royalty model and its strategic position within the AI supply chain.

Vicor  ·  Updated Oct 21

Grupo Aeroportuario del Pacífico is moving significantly higher today following the release of its third-quarter 2026 financial results, which featured a 21.8 percent year-over-year increase in total revenue and a 19.2 percent rise in EBITDA. Investors are responding favorably to the company's expanded operating margins and robust non-aeronautical revenue growth, which successfully offset a modest decline in passenger traffic. This company-specific momentum is driven by strong operational efficiency and the strategic integration of Cross Border Xpress operations.

Grupo Aeroportuario del Pacifico  ·  Updated Oct 21

TransUnion is moving significantly higher today following the launch of its industry-first Credit Washing and Synthetic Fraud Scores, which provide organizations with the first adverse-actionable solutions to combat synthetic identity fraud. The stock is also benefiting from positive momentum after its Branded Call Display was named one of TIME's Best Inventions of 2026 and as investors anticipate the company's upcoming third-quarter earnings report. This upward movement appears to be company-specific, driven by these recent technological innovations and strategic product expansions.

TransUnion  ·  Updated Oct 21

Pulse Biosciences (PLSE) is experiencing a significant upward move today, likely driven by continued investor optimism following the recent announcement of a commercial and clinical partnership with the Clayman Thyroid Center and the successful completion of enrollment in its NANOPULSE-AF pivotal clinical trial. These key milestones have been reinforced by recent analyst upgrades and price target increases to as high as $60, reflecting strong market confidence in the company’s proprietary nanosecond Pulsed Field Ablation technology. The stock's performance appears to be company-specific, fueled by these significant clinical and regulatory advancements rather than broader market trends.

Pulse Biosciences  ·  Updated Oct 20

HubSpot is moving significantly higher today as investors react to management's reaffirmation of its Q3 and fiscal year 2026 financial guidance, which has bolstered confidence following a recent 7% workforce reduction. The stock's upward momentum is further supported by positive market sentiment regarding the company's AI integration strategy and reports indicating that a large majority of its customers plan to increase their AI-related spending in the coming year. This move appears to be a company-specific rebound as the market weighs recent cost-cutting measures against a steady growth outlook in the enterprise software sector.

HubSpot  ·  Updated Oct 20

Dyne Therapeutics is surging today following the release of positive clinical data from its Phase 1/2 ACHIEVE and DELIVER trials, which demonstrated significant biomarker impact and functional improvements in treatments for myotonic dystrophy type 1 and Duchenne muscular dystrophy. The stock's gains are also attributed to the pricing of an upsized 325.5 million dollar public offering of common stock at 31.00 dollars per share, signaling robust investor confidence in the company's clinical pipeline and FORCE platform. This significant movement is company-specific and stems from both the clinical breakthroughs and the successful capital raise.

Dyne Therapeutics  ·  Updated Oct 20

Parabilis Medicines is moving significantly higher today following the company's announcement that it will present updated Phase 1/2 clinical data for its lead drug candidate, zolucatetide, at the European Society for Medical Oncology Congress on October 24. The stock's gains are driven by investor anticipation for the upcoming trial readout targeting desmoid tumors and are further supported by strong insider buying activity and the company's strategic partnership with Regeneron. This upward momentum appears to be company-specific as the market reacts to the potential for positive clinical results from its Helicon discovery platform.

Parabilis Medicines, Inc.  ·  Updated Oct 20

Millrose Properties (MRP) is moving higher today following an analyst upgrade that characterized recent market fears regarding the company's buy-to-rent strategy as dramatically overdone. This positive sentiment shift suggests a recovery from the sharp sell-off earlier in October that was triggered by a critical investigative report and subsequent securities fraud class action lawsuits. The move appears to be a company-specific technical bounce as investors reassess the stock's value following its recent drop to 52-week lows.

Millrose Properties Inc Class A  ·  Updated Oct 20

Moderna is one of the top losers today as investors engage in profit-taking and de-risking ahead of the detailed Phase 3 melanoma data presentation scheduled for October 24 at the ESMO Congress. The downward pressure is driven by analyst reports characterizing the stock's massive 2026 rally as overextended, with the current share price trading significantly above consensus fundamental estimates and fair value targets. This movement appears to be a company-specific valuation correction as the market recalibrates expectations for the upcoming clinical trial results.

Moderna  ·  Updated Oct 20

Viking Therapeutics shares are surging today following the initiation of the SUNRISE Phase 3 clinical program for its oral obesity treatment, VK2735, and positive maintenance data demonstrating that reduced dosing frequencies can preserve up to 97 percent of weight loss. The stock is also benefiting from a recent 575 million dollar capital raise that de-risks the company's financial position as it enters expensive pivotal trials. This company-specific move highlights strong investor confidence in Viking's ability to compete in the chronic weight-management market with both oral and injectable formulations.

Viking Therapeutics  ·  Updated Oct 21

Enliven Therapeutics is trading higher today following a positive research note from H.C. Wainwright, which raised its price target to $73 and issued optimistic long-term earnings estimates for the company. This bullish sentiment is further supported by recent regulatory progress, specifically the company's alignment with the FDA on the design of its pivotal Phase 3 ENABLE-2 trial for relcobatinib. The stock's gains reflect investor confidence in the company's clinical development path and its robust cash position that extends into 2030, effectively overcoming a recent downgrade to sell by Zacks Research.

Enliven Therapeutics  ·  Updated Oct 20

Liquidia Corporation is moving significantly higher today following the announcement of a global settlement with United Therapeutics that resolves all pending patent and antitrust litigation between the two companies. This pivotal agreement secures the uninterrupted commercialization of Liquidia's lead product, YUTREPIA, for pulmonary arterial hypertension and removes a major legal overhang that had previously pressured the stock. The rally is further supported by positive analyst commentary and a sharp recovery in investor sentiment as the market re-rates the company's stabilized commercial outlook.

Liquidia Technologies  ·  Updated Oct 20

Merck KGaA is trading significantly higher today following the announcement of a definitive agreement to acquire biotechnology company Silence Therapeutics for approximately $1.3 billion in an all-cash transaction. The acquisition is a strategic move to bolster the company's rare disease pipeline with the addition of divesiran, a Phase 3-ready siRNA therapy for polycythemia vera. This expansion into advanced genomic medicines has generated strong investor optimism regarding the company's long-term growth in the hematology and specialty medicine sectors.

Definium Therapeutics  ·  Updated Oct 20

Liberty Global shares are rising today following a significant upgrade from New Street Research, which raised its rating from Neutral to Buy and set a 14.00 dollar price target, citing an attractive valuation near 52-week lows. The upward momentum is further supported by news that the company's joint venture, Nexfibre, is contesting regulatory opposition to its 2 billion pound acquisition of the fibre network Netomnia. This company-specific rally stands in contrast to a broader market that remained largely flat, as investors focused on the potential for value-unlocking strategic moves and management's commitment to supporting the share price.

Liberty Global A  ·  Updated Oct 21

Wipro is moving significantly higher today due to sustained post-earnings momentum following its fiscal second-quarter 2027 results, which showcased a 50-basis-point expansion in operating margins to 16.5% and strong operating cash flow. Investors are responding positively to the company's 15,000 crore share buyback program and its growing pipeline of artificial intelligence-led deals, which have mitigated concerns over a cautious revenue guidance. The stock's gains are also being fueled by a broader rally in the Indian IT sector as market sentiment improves across the industry following resilient quarterly performances from major peers.

Wipro  ·  Updated Oct 21

Oruka Therapeutics is trading significantly higher today following a reaffirmation of a Buy rating by BTIG and sustained investor optimism surrounding its clinical pipeline. The upward momentum is primarily driven by anticipation for upcoming Phase 2b clinical data readouts for its lead candidate, ORKA-001, which are expected in the fourth quarter of 2026. This move appears to be company-specific, reflecting strong analyst confidence and a high consensus price target that suggests substantial upside potential.

Oruka Therapeutics  ·  Updated Oct 20

nCino's stock is moving significantly higher today, likely driven by continued positive momentum following a recent analyst upgrade from Stephens, which resumed coverage of the company with an Overweight rating. This bullish sentiment is further supported by the market's reaction to the company's recent launch of its AI-powered Loan Officer Productivity Suite and new partnerships aimed at automating SBA lending. The upward movement appears to be company-specific, reflecting investor optimism regarding nCino's aggressive integration of artificial intelligence into its cloud-based banking solutions.

nCino  ·  Updated Oct 20

Maas Group Holdings is falling significantly today as investors continue to react to the collapse of the 5 billion dollar initial public offering of Firmus Grid, an AI data center operator in which Maas holds a 3.2 percent equity stake. The failed listing has created substantial uncertainty regarding the valuation of the company's investment and the durability of its 1.1 billion dollar electrical infrastructure order book tied to Firmus projects. Despite the company's recent initiation of a large-scale share buy-back program to support the price, the stock remains under pressure as the market reassesses the risks associated with its heavy exposure to the stalled AI infrastructure rollout.

Highest Performances Holdings  ·  Updated Oct 20

Doximity shares are rising significantly today following the announcement of a strategic partnership with Wolters Kluwer Health to integrate UpToDate’s evidence-based clinical content into its Doximity Ask artificial intelligence platform. The stock is also benefiting from a broader sector-wide rally in health technology, with investors showing increased optimism for digital health platforms and AI-driven clinical decision tools.

Doximity  ·  Updated Oct 20

Q2 Holdings (QTWO) is moving significantly higher today, building on positive momentum from the previous session where shares rose 6 percent amid a broader rally in the technology and IT services sector. Investor sentiment is being driven by anticipation of the company's upcoming third-quarter earnings release scheduled for October 28, 2026, and a Zacks Rank 1 (Strong Buy) rating that highlights optimistic earnings prospects. The stock's performance appears to be a combination of sector-wide strength and specific enthusiasm for its near-term financial results.

Q2 Holdings  ·  Updated Oct 21

Strive, Inc. (ASST) is moving significantly higher today following the successful closing and settlement of its upsized $630 million offering of Series A Perpetual SATS Preferred Stock, which is scheduled to begin trading on the Nasdaq today. This major capital raise is being paired with positive market sentiment surrounding the company's aggressive Bitcoin treasury strategy, including the recent announcement that it acquired an additional 4,045 bitcoins to bring its total holdings to 36,818 BTC.

Strive Inc  ·  Updated Oct 20

Vertex, Inc. (VERX) is trading significantly higher today, driven by positive technical momentum following a bullish moving average crossover and a recent analyst upgrade. The stock is also seeing increased investor interest due to reports highlighting its undervalued status ahead of the third-quarter earnings release scheduled for November 4, 2026. This upward move appears to be company-specific, fueled by a combination of technical buy signals and favorable valuation sentiment.

Vertex  ·  Updated Oct 21

Abivax (ABVX) shares are rising significantly today following the presentation of positive Phase 3 maintenance data for its lead drug candidate, obefazimod, at the United European Gastroenterology (UEG) Week 2026. The stock's upward momentum is further supported by Guggenheim reiterating a Buy rating and a $175 price target, citing the drug's superior efficacy profile in ulcerative colitis compared to emerging competitors. This clinical progress reinforces investor confidence in the company's strategic timeline for a planned regulatory submission by the end of 2026.

Abivax SA Sponsored ADR  ·  Updated Oct 21

Asana (ASAN) is experiencing a significant decline today as part of a broader sell-off in the enterprise software sector, driven by escalating investor concerns over the high capital requirements and financing costs associated with AI infrastructure. This downward momentum is further exacerbated by recent analyst updates, including a "Hold" rating issued on October 17, which highlighted structural risks to the company's seat-based revenue model and margin pressure from its transition toward AI-integrated products. The move appears to be a continuation of the volatility seen following its mixed second-quarter earnings report, where soft forward guidance and contracting gross margins overshadowed current performance.

Asana  ·  Updated Oct 20

BitMine Immersion Technologies is moving significantly higher today after announcing that its total holdings of cryptocurrency, cash, and marketable securities have reached a valuation of 15.1 billion dollars. The primary catalyst is the disclosure that the company now controls 6.04 million Ethereum tokens, approximately 4.9 percent of the total supply, effectively positioning the firm as a massive institutional treasury and leveraged proxy for the Ethereum network. This update, coupled with the company's goal of reaching a 5 percent stake in the total ETH supply, has driven strong investor demand and positive momentum in the stock.

BitMine Immersion Technologies  ·  Updated Oct 20

3M Company shares are surging following third-quarter 2026 financial results that exceeded analyst expectations and the announcement of a major strategic partnership with Amazon. The company raised its full-year adjusted earnings guidance and issued warrants to Amazon tied to a potential 6 billion dollars in cumulative sales of 3M’s optical connectivity and data center products over the next seven years. This company-specific rally reflects investor optimism regarding 3M's successful expansion into the high-growth artificial intelligence infrastructure and data center markets.

3M  ·  Updated Oct 21